arrow
J

Joshua A. Hill

university of washington
H指数:45
被引数:9,421

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response

B细胞系靶向car-t细胞治疗对体液免疫和疫苗诱导的抗体反应的影响

2026-04-070
OAAI
Cytomegalovirus Viral Load Continues to Predict Poor Outcomes in Adults and Children Despite Improved Hematopoietic Cell Transplantation Success

巨细胞病毒病毒载量持续预测成人和儿童的不良结局,尽管造血细胞移植成功率有所提高

2025-11-011
OAAI
Erratum to <[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>

勘误:《免疫效应细胞相关噬血细胞性淋巴组织细胞增多症样综合征》\[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9\]

2025-10-300
OAAI
Opportunities to improve antibiotic stewardship, and identification of blood biomarkers associated with bacteremia following CAR-T cell therapy

改善抗生素合理使用的机会,以及CAR-T细胞疗法后菌血症相关血液生物标志物的鉴定

2025-07-310
PRE
ELISPOT as a predictor of clinically significant cytomegalovirus infection after hematopoietic cell transplantation in letermovir recipients

ELISPOT 作为接受莱特莫韦治疗的造血细胞移植患者中临床显著巨细胞病毒感染的预测指标

2025-05-060
PRE
T Cell Immune Response to Influenza Vaccination When Administered Prior to and Following Autologous Chimeric Antigen Receptor-Modified T Cell Therapy

T细胞对流感疫苗接种的免疫反应:在自体嵌合抗原受体修饰T细胞治疗前后给药

2025-05-011
PRE
Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies
2024-10-0110
OAAI
Clinical Utility of Plasma Microbial Cell-Free DNA Sequencing Among Immunocompromised Patients With Pneumonia
2024-07-222
OAAI
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study
2024-05-277
PRE